Paxus PM Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing Local Product Insert

Full Prescribing Info

Adverse Reactions

Adverse Events from Single Therapy in Breast Cancer: Adverse events in the following table are based on the experience of clinical study in 41 patients with metastatic breast cancer who received single therapy of PAXUS PM at an initial dose of 300 mg/m² over 3 hours. (See Table 4.)

Click on icon to see table/diagram/image

Adverse Events from First-line treatment for NSCLC combination therapy: The incidence rate of adverse events in the following table are based on the experienced of 69 patients with NSCLC enrolled in a phase II clinical study who received PAXUS PM in combination with cisplatin.
All 69 patients, who were enrolled in a phase II study and received PAXUS PM, experienced more than one adverse events. Gastrointestinal toxicities and dermatology/skin toxicities were most common by 87.0% (60/69) and 87.0% (60/69) among adverse events experienced by body system, followed by neurological toxicities (81.2%, 56/69), blood/bone marrow toxicities (78.3%, 54/69), and musculoskeletal toxicities (71.0%, 49/69). (See Table 5.)

Click on icon to see table/diagram/image

View ADR Monitoring Form

Paxus PM Adverse Reactions

paclitaxel

Manufacturer:

Samyang Holdings Corporation

Distributor:

Pacific Healthcare